Selective Tyrosine Kinase 2 Targeting for the Management of Immune-mediated Inflammatory Skin Diseases: A New Paradigm

Tyrosine kinase 2 has emerged as a compelling therapeutic target in dermatology because of its central position within the interleukin IL-23/T-helper 17, interleukin-12/T-helper 1, and type I interferon signaling pathways that underlie many immune-mediated inflammatory skin diseases. Unlike conventional Janus kinase inhibitors, which bind the catalytic domain through ATP-competitive mechanisms, selective tyrosine kinase 2 inhibitors act allosterically on the regulatory pseudokinase (Janus kinase homology 2) domain, a distinction that confers a high degree of biochemical selectivity; whether this translates into a more favorable long-term safety profile has not been established in comparative clinical trials. Deucravacitinib is the first agent of this class approved for moderate-to-severe plaque psoriasis and, more recently, psoriatic arthritis, while several further selective inhibitors are advancing through clinical development. Among these, zasocitinib and envudeucitinib have demonstrated efficacy in phase II and phase III clinical trials, further supporting the therapeutic potential of selective tyrosine kinase 2 inhibition across immune-mediated skin diseases. Beyond psoriasis, encouraging signals have been reported across a range of conditions, including cutaneous lupus erythematosus, lichen planus, and lichen planopilaris, with ongoing investigation in vitiligo and hidradenitis suppurativa. Responses have, however, proved indication dependent rather than uniform, with limited or inconsistent benefit in localized pustular forms of psoriasis and alopecia areata. This review summarizes the biology of tyrosine kinase 2, the rationale for its selective inhibition, and the current therapeutic landscape with completed and ongoing clinical evidence, underscoring that clinical utility appears to track the cytokine biology driving each disease.

Authors

Institutions

Publication Details

Journal
American Journal of Clinical Dermatology
Published
2026-11-16
DOI
https://doi.org/10.1007/s40257-026-01095-2
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Selective Tyrosine Kinase 2 Targeting for the Management of Immune-mediated Inflammatory Skin Diseases: A New Paradigm

Ioannis‐Alexios Koumprentziotis, David Aldo De Luca, Diamant Thaçi
American Journal of Clinical Dermatology
Psoriasis: Treatment and Pathogenesis
article

Selective Tyrosine Kinase 2 Targeting for the Management of Immune-mediated Inflammatory Skin Diseases: A New Paradigm

Ioannis‐Alexios Koumprentziotis, David Aldo De Luca, Diamant Thaçi
article en

Abstract

Tyrosine kinase 2 has emerged as a compelling therapeutic target in dermatology because of its central position within the interleukin IL-23/T-helper 17, interleukin-12/T-helper 1, and type I interferon signaling pathways that underlie many immune-mediated inflammatory skin diseases. Unlike conventional Janus kinase inhibitors, which bind the catalytic domain through ATP-competitive mechanisms, selective tyrosine kinase 2 inhibitors act allosterically on the regulatory pseudokinase (Janus kinase homology 2) domain, a distinction that confers a high degree of biochemical selectivity; whether this translates into a more favorable long-term safety profile has not been established in comparative clinical trials. Deucravacitinib is the first agent of this class approved for moderate-to-severe plaque psoriasis and, more recently, psoriatic arthritis, while several further selective inhibitors are advancing through clinical development. Among these, zasocitinib and envudeucitinib have demonstrated efficacy in phase II and phase III clinical trials, further supporting the therapeutic potential of selective tyrosine kinase 2 inhibition across immune-mediated skin diseases. Beyond psoriasis, encouraging signals have been reported across a range of conditions, including cutaneous lupus erythematosus, lichen planus, and lichen planopilaris, with ongoing investigation in vitiligo and hidradenitis suppurativa. Responses have, however, proved indication dependent rather than uniform, with limited or inconsistent benefit in localized pustular forms of psoriasis and alopecia areata. This review summarizes the biology of tyrosine kinase 2, the rationale for its selective inhibition, and the current therapeutic landscape with completed and ongoing clinical evidence, underscoring that clinical utility appears to track the cytokine biology driving each disease.

American Journal of Clinical Dermatology
University Hospital Schleswig-Holstein (DE), University of Lübeck (DE)
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon